Neurocrine Biosciences (NASDAQ:NBIX) Director George Morrow Sells 7,500 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $145.79, for a total transaction of $1,093,425.00. Following the completion of the transaction, the director owned 10,386 shares of the company’s stock, valued at $1,514,174.94. This trade represents a 41.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $164.85 on Wednesday. The stock has a market cap of $16.76 billion, a P/E ratio of 24.46, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The firm’s fifty day moving average price is $146.72 and its 200-day moving average price is $147.60.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 24.11% and a net margin of 18.98%. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the firm earned $2.04 earnings per share. The company’s revenue for the quarter was up 41.3% compared to the same quarter last year. On average, analysts predict that Neurocrine Biosciences, Inc. will post 7.72 earnings per share for the current year.

Hedge Funds Weigh In On Neurocrine Biosciences

Several large investors have recently modified their holdings of NBIX. Raleigh Capital Management Inc. boosted its stake in Neurocrine Biosciences by 561.8% during the third quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock worth $32,000 after buying an additional 191 shares during the period. Basecamp Wealth Advisors LLC raised its stake in shares of Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after acquiring an additional 204 shares during the period. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Neurocrine Biosciences in the first quarter valued at $33,000. TrinityBridge Ltd bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth about $45,000. Finally, Transamerica Financial Advisors LLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth about $48,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Third-quarter revenue rose 41% year over year to $1.12 billion, exceeding estimates, while EPS of $3.29 also topped consensus. Product sales surpassed $1 billion for the first time. Neurocrine raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, citing demand across its portfolio. Third-quarter results
• Positive Sentiment: Several analysts raised price targets after the results: Canaccord to $220, Piper Sandler to $215, RBC to $190, and Morgan Stanley to $185. Ratings ranged from buy/outperform to equal weight, so the target increases were broadly supportive but not uniformly bullish.
• Positive Sentiment: The company said it has begun a Phase 2 Alzheimer’s study and plans to present its neuroscience work and pipeline at the NEI Fall Congress. These updates add to investor focus on longer-term development opportunities, though the supplied reports provide limited study details. Alzheimer’s study and education update
• Negative Sentiment: Director George J. Morrow reported sales totaling 15,000 shares across transactions on November 2–3, in addition to a 300-share sale on October 30. The filings say the transactions were made under a pre-arranged Rule 10b5-1 plan, which may temper concern, and he retained 10,386 shares.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on NBIX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $204.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, October 16th. Royal Bank Of Canada lifted their price objective on Neurocrine Biosciences from $187.00 to $190.00 and gave the company an “outperform” rating in a research report on Tuesday. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 4th. Wells Fargo & Company boosted their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, UBS Group decreased their price target on shares of Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $201.55.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.